SIMBRINZA Drug Patent Profile

Which patents cover Simbrinza, and when can generic versions of Simbrinza launch?

Simbrinza is a drug marketed by Alcon Labs Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in SIMBRINZA is brimonidine tartrate; brinzolamide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the brimonidine tartrate; brinzolamide profile page.

DrugPatentWatch^® Generic Entry Outlook for Simbrinza

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 30, 2030. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SIMBRINZA

US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	10
Patent Applications:	38
Drug Prices:	Drug price information for SIMBRINZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SIMBRINZA
What excipients (inactive ingredients) are in SIMBRINZA?	SIMBRINZA excipients list
DailyMed Link:	SIMBRINZA at DailyMed

See drug prices for SIMBRINZA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SIMBRINZA

NDA:

204251

Dosage:

SUSPENSION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SIMBRINZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Prairie Eye Center	PHASE4
Sengi	PHASE4
Perrigo Company	Phase 3

See all SIMBRINZA clinical trials

Pharmacology for SIMBRINZA

Drug Class	Carbonic Anhydrase Inhibitor alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Carbonic Anhydrase Inhibitors

Paragraph IV (Patent) Challenges for SIMBRINZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SIMBRINZA	Ophthalmic Suspension	brimonidine tartrate; brinzolamide	1%/0.2%	204251	1	2022-08-01

US Patents and Regulatory Information for SIMBRINZA

SIMBRINZA is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	SIMBRINZA	brimonidine tartrate; brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	204251-001	Apr 19, 2013		RX	Yes	Yes			Y
Alcon Labs Inc	SIMBRINZA	brimonidine tartrate; brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	204251-001	Apr 19, 2013		RX	Yes	Yes			Y

Expired US Patents for SIMBRINZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alcon Labs Inc	SIMBRINZA	brimonidine tartrate; brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	204251-001	Apr 19, 2013

EU/EMA Drug Approvals for SIMBRINZA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Simbrinza	brinzolamide, brimonidine tartrate	EMEA/H/C/003698Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.	Authorised	no	no	no	2014-07-18

International Patents for SIMBRINZA

When does loss-of-exclusivity occur for SIMBRINZA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

European Patent Office

Hong Kong

Hungary

Japan

Lithuania

Mexico

Poland

Portugal

Russian Federation

San Marino

Slovenia

South Africa

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SIMBRINZA around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2004073708
Argentina	077126
Argentina	122017
Australia	2010262898

Supplementary Protection Certificates for SIMBRINZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	C300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	92462	Luxembourg		PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225
1631293	2014/041	Ireland		PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
1631293	300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225

Last updated: July 15, 2026

SIMBRINZA market dynamics and financial trajectory (revenue drivers, pricing, exclusivity, and competitive risk)

Executive summary: SIMBRINZA (brinzolamide and brimonidine tartrate ophthalmic suspension) is an established, branded ophthalmology combination product used for lowering intraocular pressure in glaucoma and ocular hypertension. Its revenue trajectory is driven by (1) U.S. formulary access for chronic therapy, (2) competitive pressure from alternative IOP-lowering regimens (including fixed-combination branded and generic adjuncts), and (3) ongoing patent and regulatory timelines that shape generic entry risk. Key downside risk comes from loss of exclusivity, Paragraph IV challenges on relevant Orange Book listings, and substitution dynamics within common glaucoma treatment pathways.

---

How is SIMBRINZA performing financially, and what drives its revenue trajectory?

Short answer: SIMBRINZA’s financial performance is tied to chronic patient persistence, payer coverage in glaucoma, and competitive substitution as lower-cost alternatives expand. In ophthalmology, revenue is typically resilient while branded fixed combinations maintain formulary placement, then compresses after material generic penetration of component molecules or close regimen substitutes.

What are the core financial drivers for SIMBRINZA?

1. Chronic use and persistence: Patients generally remain on long-term therapy; discontinuations and switching drive demand.
2. Payer formulary tiering: Net sales depend on rebate structure and placement versus other fixed combinations and single agents.
3. Clinic prescribing behavior: Ophthalmologists often start with monotherapy and titrate; fixed combinations are adopted when combination therapy is preferred for adherence or IOP targets.
4. Channel and stocking: Pharmacy ordering patterns in specialty channels influence quarterly revenue timing.

What market dynamics matter most in glaucoma fixed combinations?

• Switching risk: If a payer limits a branded combination to narrower criteria, prescribers shift to alternative branded or generic regimens.
• Price erosion: Even with slower volume decline, branded ophthalmology can face margin pressure as generics of one or both actives expand or as wholesalers push lower-cost equivalents.
• Therapy sequencing: SIMBRINZA is one option within a crowded IOP-lowering landscape, so its growth is more constrained than new-mechanism launches.

---

What patents protect SIMBRINZA, and how does patent life shape future sales?

Short answer: SIMBRINZA’s exclusivity and patent estate control when generic ophthalmic suspensions can enter using brinzolamide/brimonidine or close variants, shaping the forward-looking revenue outlook through the exclusivity-to-expiration bridge.

What patent types typically matter for ophthalmic fixed combinations?

• Composition-of-matter for the drug product or combination.
• Formulation patents for ophthalmic suspension characteristics (particle size distribution, viscosity, stabilizers, preservatives).
• Method-of-use patents covering glaucoma/OHT dosing regimens.
• Manufacturing process patents (sterility, mixing order, controlled release, mixing times).

How do patent cliffs translate into commercial impact?

• Orange Book listing expiration often sets the date when ANDA filers can seek generic approval.
• Paragraph IV litigation can delay approval and extend market exclusivity through settlement terms.
• Design-around pathways can reduce delay if a competitor can challenge listed patents effectively.

---

When does SIMBRINZA lose exclusivity, and what generic entry scenarios are realistic?

Short answer: The market impact depends on the Orange Book status of the listed patents tied to SIMBRINZA’s NDA and the associated expiration schedule, plus whether ANDA entrants file Paragraph IV certifications and win or settle.

What generic entry scenarios typically occur in combination eye drops?

1. Component-level substitution: Even if the fixed combination is protected, patients can be switched to generic brinzolamide + generic brimonidine as separate products.
2. ANDA entry for the fixed combination: Competitors seek approval for the combination product if patent coverage is cleared.
3. Launch after patent expiration but before settlement: If litigation ends without a pay-for-delay style settlement, entry can occur promptly after the relevant listed patents expire.
4. Partial exclusivity vs broad patent coverage: Some patents expire earlier than others, allowing entry of certain strengths, packaging, or formulation parameters depending on protection scope.

---

What is the Orange Book status of SIMBRINZA?

Short answer: Orange Book status (listed patents, expiration dates, and exclusivity blocks) determines the credible window for ANDA-driven competition and the basis for Paragraph IV challenges.

What to track in the Orange Book for SIMBRINZA

• NDA holder and product listing
• Listed patents with staggered expirations
• Exclusivity types (if present)
• Relevant patent claims mapped to the drug product versus the active ingredients

---

Which companies are challenging SIMBRINZA with Paragraph IV ANDAs?

Short answer: Paragraph IV ANDA filers determine the timing and probability of generic competition. Litigation outcomes or settlements drive delay length.

What matters in Paragraph IV challenges for revenue exposure

• Certifications: “IV” on specific patents is the trigger for automatic stays (if conditions are met).
• Court outcomes: Dismissal, settlement, or favorable rulings affect entry timing.
• Settlement terms: If a settlement includes an agreed design and market-launch date, that date becomes the commercial inflection point.

---

What patent litigation affects SIMBRINZA, and what settlement terms changed launch timelines?

Short answer: SIMBRINZA’s commercialization path is affected by whether listed patents were litigated and whether any settlement delayed generic approval.

Key litigation and settlement variables that drive market impact

• Number of asserted patents
• Whether the NDA sponsor secured injunctions
• Whether the case resolved with a stipulated generic launch date
• Whether partial lifting of the stay occurred

---

How does SIMBRINZA compare with competing glaucoma fixed combinations on market risk?

Short answer: Market risk depends on whether competitors offer stronger efficacy perceptions, better dosing convenience, or improved payer access. In fixed-combination glaucoma therapy, small perceived differences can shift share.

Competitive set structure

SIMBRINZA competes against:

• Other fixed combinations targeting IOP reduction (alpha agonist + carbonic anhydrase inhibitor combinations, among others)
• Branded monotherapies that can be covered more favorably
• Multi-generic regimens using separate generic components

What share factors typically favor competitors

• Lower net price after rebates
• Better formulary access
• Stronger persistence outcomes in real-world settings
• Convenience (fewer drops, once-daily regimens)

What share factors typically favor SIMBRINZA

• Established clinician familiarity
• Fit for patients needing combination therapy
• Fixed regimen adherence benefits versus separate bottles

---

What formulations are protected for SIMBRINZA, and can generics design around?

Short answer: Formulation patents can block “same actives, different formulation” generic strategies if the listed claims cover essential product characteristics of the ophthalmic suspension.

Design-around vectors for ophthalmic suspensions

• Particle size and suspension stability parameters
• Preservative system and concentration
• Viscosity modifiers that affect comfort and ocular retention
• Manufacturing controls that influence drug particle distribution

---

Does SIMBRINZA face biosimilar risk, or is it strictly an ANDA/generic story?

Short answer: SIMBRINZA is a small-molecule ophthalmic combination, so biosimilar risk is not the primary threat. Competitive pressure comes from ANDA/generic equivalents, component-level substitution, and fixed-combination competitors.

---

What is the FDA and regulatory status of SIMBRINZA, and how does it affect future launch timelines?

Short answer: Regulatory status shapes timing for generic approvals and label-based substitution. For legacy ophthalmics, the FDA-related lever is the ANDA approval path once patent and exclusivity barriers clear.

Regulatory milestones that matter commercially

• NDA approval history and label indications
• Hatch-Waxman framework for generic approvals (Orange Book-linked patents)
• Post-marketing label updates that can affect switching decisions

---

What is the revenue exposure for SIMBRINZA under generic launch scenarios?

Short answer: Revenue exposure is highest when (1) patent barriers fall, (2) a fixed-combination generic launches, and (3) payers align coverage to lower net prices. Component-level substitution often compresses revenue even before a fixed-combination generic launch.

Revenue exposure map (typical ophthalmology pattern)

• Pre-expiration: stable, rebated branded sales with moderate switching
• Patent-expiration window: acceleration of prescription switching, increased rebate pressure
• Post-fixed-combination entry: sharper net sales decline if payers change formulary tiering
• Longer horizon: consolidation around the lowest net cost regimen

---

How strong is the patent estate for SIMBRINZA, and what does it imply for downside risk?

Short answer: Patent strength depends on how many distinct listed patents cover the fixed combination product and whether multiple patents remain active at the time of anticipated generic entry.

Patent strength indicators

• Count of active Orange Book patents
• Breadth of claims tied to essential formulation and combination structure
• Likelihood of successful design-around
• Litigation history (volume of asserted patents and outcomes)

---

Key Takeaways

• SIMBRINZA’s financial trajectory is primarily a function of fixed-combination chronic glaucoma market dynamics, not breakthrough-cycle growth.
• Revenue is driven by payer formulary placement, persistence, and rebate economics.
• The biggest commercial inflection points come from Orange Book patent expirations, Paragraph IV litigation, and settlement-driven launch delays.
• Competitive risk is likely to intensify through component-level substitution and fixed-combination competitors with favorable net pricing.

---

FAQs

1. How do component-level generics (brinzolamide and brimonidine) affect SIMBRINZA net sales even if the fixed combination remains protected?
2. What formulary strategy do payers use for glaucoma fixed combinations, and how does it shift SIMBRINZA prescribing?
3. What are the typical rebate and pricing mechanisms that cause branded ophthalmology revenue compression after generic entry?
4. How do formulation quality differences (suspension stability, particle size) influence whether a generic can be considered “therapeutically equivalent” for switching?
5. When a Paragraph IV case is settled, what launch-date terms most directly determine SIMBRINZA revenue impact?

---

References

No sources were cited.

DrugChatter Q&A for SIMBRINZA

Simbrinza eye drops discontinued?
Buy simbrinza online?